|
- 2018
Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl?DOI: 10.1007/s40120-018-0116-x Keywords: Bioequivalence, Copemyl?, Equivalence trials, Glatiramoid, Glatiramer acetate, Multiple sclerosis, Non-biological complex drugs Abstract: Enhanced digital feature
|